Prabhakar Kedar

Dr. Prabhakar Kedar

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2019 in Cytometry Part B: Clinical Cytometry
Verified
Journal Article
Closed access
PDF file
TMTejashree Anil More
Tejashree Anil More
BDBhavik Dalal
Bhavik Dalal
RDRati Devendra
Rati Devendra
PWPrashant Warang
Prashant Warang
ASAruna Shankarkumar
Aruna Shankarkumar
PKPrabhakar Kedar
Prabhakar Kedar

3 January 2020 in Human Mutation
Verified
Journal Article
Closed access
PDF file
VGVinod Gupta
Vinod Gupta
AKAnuja Kulkarni
Anuja Kulkarni
PWPrashant Warang
Prashant Warang
RDRati Devendra
Rati Devendra
ACAshish Chiddarwar
Ashish Chiddarwar
PKPrabhakar Kedar
Prabhakar Kedar

10 August 2019 in International Journal of Hematology
Verified
Journal Article
Closed access
PDF file
PKPrabhakar Kedar
Prabhakar Kedar
HHHideo Harigae
Hideo Harigae
EIEtsuro Ito
Etsuro Ito
HMHideki Muramatsu
Hideki Muramatsu
SKSeiji Kojima
Seiji Kojima
MMManisha Madkaikar
Manisha Madkaikar

27 February 2018 in Hematology
Verified
Journal Article
Closed access
PKPrabhakar Kedar
Prabhakar Kedar
VGVinod Gupta
Vinod Gupta
PWPrashant Warang
Prashant Warang
ACAshish Chiddarwar
Ashish Chiddarwar
MMManisha Madkaikar
Manisha Madkaikar
Objective: To investigate the cause of recessive congenital methemoglobinemia (RCM) in Indian families and to identify molecular defect associated with RCM. Methods: Eight cases of RCM have been addressed to our laboratory in order to investigate the cause of cyanosis associated with genetic disorders. NADH-cytochrome b5 reductase (cytb5r) enzyme activities were measured by standard methods, and molecular analysis was performed by polymerase chain reaction (PCR) followed by DNA sequencing. The interpretation of mutation effect and the molecular modeling were performed by using specific software DEEP VIEW SWISS-PDB VIEWER and Pymol molecular graphics program. Results and Discussion: Eight index cases from four unrelated families were referred for the cause of cyanosis. All patients showed mild to moderate cyanosis without mental retardation or any neurologic abnormalities. The methemoglobin levels were in the range of 11.5–22.41% with 50–70% reduction in CYTB5R activity. Spectroscopic analysis of the hemolysate showed normal peaks suggesting the absence of Hb-M. Molecular characterization showed a novel homozygous mutation p.Arg192Cys in CYB5R3 gene is an evolutionarily conserved position located in exon 7 in all eight index cases. The substitution of Cys is located on the interface of two domains of NADH-binding domain and is close proximity to the adenosine moiety would preclude the reciprocal ionic interaction (salt bridge) between Arg192 and Ile97 and may influence binding of the NADH coenzyme is hypothesized to cause disruption of hydrogen bonding and instability. Our study indicated that novel homozygous mutation p.Arg192Cys in CYB5R3 gene present in eight cases and the possibility of high prevalence of heterozygous in Indian population causing Type I RCM.

28 February 2020 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
TMTejashree Anil More
Tejashree Anil More
RDRashmi Dongerdiye
Rashmi Dongerdiye
RDRati Devendra
Rati Devendra
PWPrashant P. Warang
Prashant P. Warang
PKPrabhakar Kedar
Prabhakar Kedar

18 October 2018 in Journal of Clinical Pathology
Verified
Journal Article
Closed access
PDF file
PKPrabhakar Kedar
Prabhakar Kedar
VGVinod Gupta
Vinod Gupta
RDRashmi Dongerdiye
Rashmi Dongerdiye
ACAshish Chiddarwar
Ashish Chiddarwar
PWPrashant Warang
Prashant Warang
MMManisha R Madkaikar
Manisha R Madkaikar
Glucose-6-phosphate isomerase (GPI) deficiency is an autosomal recessive genetic disorder causing congenital haemolytic anaemia (CHA). Diagnosis of GPI deficiency by the biochemical method is unpredicted. Molecular diagnosis by identifying genetic mutation is the gold standard method for confirmation of disease, but causative genes involved in CHA are numerous, and identifying a gene-by-gene approach using Sanger sequencing is also cumbersome, expensive and labour intensive. Recently, next-generation targeted sequencing is more useful in the diagnosis of unexplained haemolytic anaemia. We used targeted next-generation sequencing (NGS) clinical panel for diagnosis of unexplained haemolytic anaemia in two Indian patients which were pending for a long time. All possible causes of haemolytic anaemia were found within normal limit. NGS by clinical exome panel revealed homozygous novel missense mutation in exon 12, c.1009G>A (p.Ala337Thr) in both patients. We further confirm by measuring red blood cell GPI activity in the patients and showed deficiency whereas parents were having intermediate activity. c.1009G>A mutation was also confirmed by Sanger sequencing of exon 12 of GPI gene. The structural–functional analysis by bioinformatics software like Swiss PDB, PolyPhen-2 and PyMol suggested that this pathogenic variant has a direct impact on the structural rearrangement at the region near the active site of the enzyme. This rapid and high-performance targeted NGS assay can be configured to detect specific CHA mutations unique to an individual defect, making it a potentially valuable method for diagnosis of unexplained haemolytic anaemia.